Cardiovascular diabetology
Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW.
Peter Rossing, Morten Lindhardt, Christian Klyver Tikkanen, Jyothi Menon, Juliette Cattin, Barnaby Hunt, Samuel J P Malkin, Barrie Chubb, Tina Damgaard, Rikke Borg
Published: 202510.1186/s12933-025-03002-1
Abstract
BACKGROUND: The FLOW clinical trial recently demonstrated that the glucagon-like peptide-1 receptor agonist once-weekly semaglutide 1 mg was associated with kidney- and cardio-protective effects (the latter already shown in the SUSTAIN 6 trial) compa…
Preview only. Read the full abstract at the source